ScreenerHero

ABOS Acumen Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · acumenpharm.com
2.100USD+3.45%Mkt Cap: 151.87M $P/E: —

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap151.87M USD
Enterprise Value68.25M USD
Revenue (TTM)—
Gross Profit-86.79M USD
Net Income (TTM)-121.33M USD
Revenue/Share—
Last Price2.100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.42
PEG—
EV/EBITDA-0.65
EV/Revenue—
P/S—
P/B2.56
EPS (TTM)-1.64
EPS (Forward)-1.43
52W Range
1.21037% of range3.600
52W High3.600 USD
52W Low1.210 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-172.28%
ROA-98.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-115.54M USD
CapEx (TTM)88.00K USD
FCF Margin—
FCF Yield-37.21%
Net Debt-78.55M USD
Net Debt/EBITDA0.75
Balance Sheet
Debt/Equity0.44
Current Ratio2.47
Quick Ratio2.38
Book Value/Sh0.79 USD
Cash/Share1.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.600 USD
Upside (mean)+261.9%
Target Range5.000 USD – 10.00 USD
5.000+261.9% to mean10.00
# Analysts5
Ownership
Shares Out.72.32M
Float37.05M
Insiders6.79%
Institutions66.59%
Short Interest
Short Ratio7.6d
Short % Float5.56%
Short % Out.3.88%
Shares Short2.80M
Short (prev mo.)3.23M
Technical
SMA 502.608 (-19.5%)
SMA 2002.508 (-16.3%)
Beta0.33
S&P 52W Chg16.45%
Avg Vol (30d)519.66K
Avg Vol (10d)708.97K
Technical Indicators
RSI (14)36.4
MACD-0.1742
MACD Signal-0.1230
MACD Hist.-0.0511
BB Upper3.175 USD
BB Middle2.464 USD
BB Lower1.753 USD
BB Width57.71%
ATR (14)0.1857 USD
Vol Ratio (20d)1.08x